Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessStocksSun Pharmaceutical Industries Stock Falls 2.02% in Today's Trading Session

    Sun Pharmaceutical Industries Stock Falls 2.02% in Today's Trading Session

    With the stock's current price at Rs 1,651.20, Sun Pharmaceutical Industries experienced a downturn in today's session, influenced by bearish investor sentiment.

    Alpha Desk
    June 17, 2025 / 10:31 IST
    Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer
       
       
      26 Aug, 2025 12:21
      Volume
      Todays L/H
      More

      During today's session, shares of Sun Pharmaceutical Industries experienced a decline of 2.02%, with the price settling at Rs 1,651.20. This movement reflects a very bearish sentiment, according to a Moneycontrol analysis as of June 12, 2025. Sun Pharmaceutical Industries is a significant constituent of the NIFTY 50 and NIFTY 100 indices, underscoring its prominent position in the Indian stock market.

      Financial Overview

      The consolidated financial performance of Sun Pharmaceutical Industries over the recent quarters and years provides context to its market valuation and investor perception.

      Quarterly Performance

      The following table summarizes the consolidated financial performance of Sun Pharmaceutical Industries over the past five quarters:

      HeadingMar 2024Jun 2024Sep 2024Dec 2024Mar 2025
      Revenue11,982.90 Cr12,652.75 Cr13,291.39 Cr13,675.46 Cr12,958.84 Cr
      Net Profit2,666.59 Cr2,871.25 Cr3,030.67 Cr2,917.54 Cr2,160.64 Cr
      EPS11.1011.8012.7012.109.00
      Annual Performance

      The annual consolidated financial performance is detailed below, providing a longer-term view of the company's financial health:

      Heading20212022202320242025
      Revenue33,498.14 Cr38,654.49 Cr43,885.68 Cr48,496.85 Cr52,578.44 Cr
      Net Profit2,284.68 Cr3,405.82 Cr8,560.84 Cr9,648.44 Cr10,980.10 Cr
      EPS12.1013.6035.3039.9045.60
      BVPS206.23212.84247.22279.69301.00
      ROE6.246.8115.1315.0415.13
      Debt to Equity0.070.020.110.040.03
      Income Statement Data

      The consolidated income statement data offers a deeper dive into the company's revenue and profitability trends.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      Sales52,578 Cr48,496 Cr43,885 Cr38,654 Cr33,498 Cr
      Other Income1,965 Cr1,354 Cr634 Cr921 Cr835 Cr
      Total Income54,543 Cr49,851 Cr44,520 Cr39,576 Cr34,333 Cr
      Total Expenditure40,559 Cr38,524 Cr34,939 Cr34,967 Cr31,392 Cr
      EBIT13,983 Cr11,326 Cr9,580 Cr4,608 Cr2,940 Cr
      Interest231 Cr238 Cr172 Cr127 Cr141 Cr
      Tax2,772 Cr1,439 Cr847 Cr1,075 Cr514 Cr
      Net Profit10,980 Cr9,648 Cr8,560 Cr3,405 Cr2,284 Cr
      Quarterly Income Statement Data

      A closer look at the quarterly income statements reveals short-term fluctuations in the company's financials.

      Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
      Sales12,958 Cr13,675 Cr13,291 Cr12,652 Cr11,982 Cr
      Other Income612 Cr465 Cr354 Cr532 Cr605 Cr
      Total Income13,571 Cr14,141 Cr13,645 Cr13,185 Cr12,588 Cr
      Total Expenditure10,268 Cr10,613 Cr9,978 Cr9,700 Cr9,699 Cr
      EBIT3,303 Cr3,527 Cr3,667 Cr3,485 Cr2,889 Cr
      Interest49 Cr51 Cr69 Cr61 Cr73 Cr
      Tax1,093 Cr558 Cr567 Cr552 Cr148 Cr
      Net Profit2,160 Cr2,917 Cr3,030 Cr2,871 Cr2,666 Cr
      Cash Flow Activities

      Cash flow data illustrates the sources and uses of cash within Sun Pharmaceutical Industries.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      Operating Activities14,072 Cr12,134 Cr4,959 Cr8,984 Cr6,170 Cr
      Investing Activities-5,306 Cr-690 Cr-7,943 Cr-5,724 Cr536 Cr
      Financing Activities-7,905 Cr-6,710 Cr2,376 Cr-5,193 Cr-5,980 Cr
      Others123 Cr-72 Cr723 Cr168 Cr-129 Cr
      Net Cash Flow983 Cr4,661 Cr115 Cr-1,764 Cr596 Cr
      Equities and Liabilities

      The equities and liabilities provide insights into the company's capital structure and obligations.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      Share Capital239 Cr239 Cr239 Cr239 Cr239 Cr
      Reserves & Surplus71,978 Cr63,426 Cr55,755 Cr47,771 Cr46,222 Cr
      Current Liabilities18,194 Cr16,984 Cr19,907 Cr17,200 Cr16,145 Cr
      Other Liabilities1,688 Cr4,811 Cr4,841 Cr4,588 Cr5,058 Cr
      Total Liabilities92,100 Cr85,462 Cr80,743 Cr69,799 Cr67,666 Cr
      Asset Details

      The asset details show how the company's resources are distributed.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      Fixed Assets20,290 Cr19,966 Cr20,680 Cr17,197 Cr16,832 Cr
      Current Assets52,624 Cr43,474 Cr39,883 Cr35,014 Cr30,442 Cr
      Other Assets19,185 Cr22,021 Cr20,179 Cr17,587 Cr20,392 Cr
      Total Assets92,100 Cr85,462 Cr80,743 Cr69,799 Cr67,666 Cr
      Other Information

      Additional details regarding contingent liabilities provide a comprehensive view.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      Contingent Liabilities0 Cr6,343 Cr7,903 Cr6,756 Cr7,057 Cr
      Key Per Share Ratios

      Per share ratios are critical for investors to assess the stock's value.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      Basic EPS (Rs.)45.6039.9035.3013.6012.10
      Diluted Eps (Rs.)45.6039.9035.3013.6012.10
      Book Value [Excl. Reval Reserve]/Share (Rs.)301.00279.69247.22212.84206.23
      Dividend/Share (Rs.)16.0013.5011.5010.007.50
      Face Value11111
      Key Margin Ratios

      Margin ratios help in evaluating the company's profitability and efficiency.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      Gross Profit Margin (%)32.7829.6427.9829.2827.84
      Operating Margin (%)27.8824.3722.2223.7321.63
      Net Profit Margin (%)20.8819.8919.508.816.82
      Key Return Ratios

      Return ratios provide insights into how effectively the company is generating returns for its investors.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      Return on Networth / Equity (%)15.1315.0415.136.816.24
      ROCE (%)19.8317.2616.0217.4414.06
      Return On Assets (%)11.8611.2010.494.684.29
      Key Liquidity Ratios

      Liquidity ratios are essential for assessing the company's ability to meet its short-term obligations.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      Current Ratio (X)2.892.562.002.041.89
      Quick Ratio (X)2.331.981.481.511.33
      Key Leverage Ratios

      Leverage ratios provide insights into the company's debt levels and its ability to cover interest expenses.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      Debt to Equity (x)0.030.040.110.020.07
      Interest Coverage Ratios (X)74.5060.2971.4088.8865.95
      Key Turnover Ratios

      Turnover ratios are used to measure how efficiently the company is utilizing its assets.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      Asset Turnover Ratio (%)0.590.580.580.560.49
      Inventory Turnover Ratio (X)0.640.680.800.780.73
      Key Growth Ratios

      Growth ratios indicate the company's growth trajectory over the years.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      3 Yr CAGR Sales (%)16.6320.3215.6015.3212.61
      3 Yr CAGR Net Profit (%)79.55105.5042.993.02-6.86
      Key Valuation Ratios

      Valuation ratios are used to assess whether the stock is overvalued or undervalued.

      Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
      P/E (x)38.0440.6227.8567.2649.40
      P/B (x)5.776.114.214.573.09
      EV/EBITDA (x)23.6226.7519.5119.3015.36
      P/S (x)7.928.025.375.684.28

      With the stock's current price at Rs 1,651.20, Sun Pharmaceutical Industries experienced a downturn in today's session, influenced by bearish investor sentiment.

      Alpha Desk
      first published: Jun 17, 2025 10:31 am

      Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

      Subscribe to Tech Newsletters

      • On Saturdays

        Find the best of Al News in one place, specially curated for you every weekend.

      • Daily-Weekdays

        Stay on top of the latest tech trends and biggest startup news.

      Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347